- Anjali Hari, MD (2024): Assistant Professor, UC Irvine
- Marisa Liu, MD (2024): Kaiser Permanente
- Travis Korenaga, MD (2023): Kaiser Hawaii
- Carolyn Haunschild, MD (2022): Assistant Professor, UCLA
- Kiran Clair, MD (2022): Assistant Professor, UC Irvine
- Diana Pearre, MD (2021): Providence Medical Institute
- Juliet Wolford, MD (2020): Assistant Professor, University of Cincinnati
- Lindsey Minion, MD (2020): Assistant Professor, Thomas Jefferson University, Philadelphia, PA
Robert S. Mannel, MD, completed the fellowship in 1989 and joined the faculty at the University of Oklahoma, where he is currently professor and chairman of the Department of Obstetrics and Gynecology. Mannel also holds the Rainbolt Family Chair in Cancer and is the director of the Oklahoma University Cancer Institute. He is the chairman of the Ovarian Committee of the National Institutes of Health/Gynecologic Oncology Group and a board examiner for the American Board of Obstetrics & Gynecology.
Joseph A. Lucci III, MD, graduated from the fellowship in 1992 and spent several years at the University of Texas-Medical Branch in Galveston, where he was associate professor and director of the fellowship program. He is currently professor and director of the Division of Gynecologic Oncology at the University of Miami School of Medicine. He is the co-leader of the Gynecologic Cancer Site Disease Group at the Sylvester Comprehensive Cancer Center and is the chairman of the Vaccines Subcommittee of the National Institutes of Health/Gynecologic Oncology Group. He continues to work in the fields of cancer immunology and tumor vaccines.
Robert A. Burger, MD, graduated from the fellowship in 1996 and spent two years at Texas Tech University before returning to UC Irvine, where he was appointed associate professor during his 10 years on the faculty in the Division of Gynecologic Oncology. While at UC Irvine, Burger ran a fully equipped angiogenesis laboratory, maintained a robust clinical practice at three sites, served as principal investigator for UC Irvine’s National Cancer Institutes/Gynecologic Oncology Group (GOG) and chaired the Institutional Review Board.
A member of both the Ovarian Cancer Committee and the Developmental Therapeutics Committee, Burger ran one of three important Phase II trials studying the activity and toxicity of the anti-vascular agent bevacizumab in managing heavily pretreated women with recurrent ovarian cancer (GOG protocol 170D). For this work, he was appointed principal investigator for the Phase III, randomized, three-arm, placebo-controlled trial of upfront therapy employing chemotherapy plus bevacizumab for women with ovarian cancer (GOG protocol 218). During the latter half of 2008, Burger joined the Fox Chase Cancer Center in Philadelphia as the associate director of research and co-director of the Ovarian Cancer Research program in the Section of Gynecologic Oncology.
Lieutenant Colonel G. Scott Rose, MD, graduated from the fellowship in 1998 and joined the staff at the Walter Reed Army Medical Center (WRAMC). He is the director of the Division of Gynecologic Oncology as well as the director of the Gynecologic Oncology Subspecialty Fellowship training program at WRAMC. Rose serves as the deputy director for the Gynecologic Disease program at WRAMC. In addition to his extensive academic commitments, Rose provided surgical care to wounded soldiers on-site in Iraq in 2005.
Diane Yamada, MD, completed the fellowship in 1999 and is now the director of the Section of Gynecologic Oncology at the University of Chicago. She is the principal investigator at the University of Chicago for the National Institutes of Health/Gynecologic Oncology Group, and her research has focused on the role of signaling pathways in the modulation of ovarian cancer metastasis. Her work has been sponsored by the Department of Defense, the American Cancer Society, the Gynecologic Cancer Foundation and the Cancer Research Foundation.
Wendy R. Brewster, MD, PhD, completed the research/clinical segment of the fellowship in 1999 and earned her PhD in epidemiology in 2000. She stayed on faculty at UC Irvine, where she was appointed director of the Gynecologic Oncology Fellowship training program and earned tenure as an associate professor in 2007. At UC Irvine, she was the co-investigator for an NCI-funded grant to study a single visit cervical cancer screening program. Brewster was also the co-principal investigator of the largest cohort of breast cancer survivors receiving hormone replacement therapy. In 2008, Brewster transitioned to the University of North Carolina at Chapel Hill where she assumed the role of director of women’s health research.
John K. Chan, MD, graduated from the fellowship in 2003 and spent four years on faculty at Stanford University, where he overhauled their research program. This led to the publication of nearly 30 manuscripts and innumerable national presentations. He has since joined the faculty at UC San Francisco as an assistant professor and has received the John A. Kerner Distinguished Professorship in Gynecologic Oncology. He is also the director of the Division of Gynecologic Oncology at UC San Francisco.
Chan has been the recipient of numerous awards, including the New Investigator Award by the Gynecologic Oncology Group/Ovarian Cancer Research Fund and the Gynecologic Cancer Foundation Research Award. He is a member of the Ovarian Committee of the National Institutes of Health/Gynecologic Oncology Group, where he has several trials under development. In 2008, he was awarded an RO3 by the National Institutes of Health for his ongoing work evaluating the practice patterns and outcomes of women at risk for ovarian cancer who undergo prophylactic oophorectomy.